Publication - 2017A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Publication

Simvastatin inhibits interferon-γ signaling by blocking activation of STAT and prevented and reversed disease in our mouse model. We conducted a small, randomized, double-blind, placebo-controlled, phase II clinical trial to test simvastatin as a treatment for vitiligo. Our study does not support the use of oral simvastatin for the treatment of vitiligo. Disparate findings in this study compared with our mouse model may be a result of dosing limitations in human beings because of potential toxicity, which is not a concern in mice.

Full text   

Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE



FAQOther Questions

  • Which skin conditions can be mistaken for vitiligo?

    Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

  • Is there a special diet for vitiligo?

    Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...